| 
						
						
						 U.S. 
						FTC requires divestitures in $13.53 billion 
						Boehringer-Sanofi deal 
   Send a link to a friend 
		[December 29, 2016] 
		WASHINGTON (Reuters) - German 
		pharmaceutical company Boehringer Ingelheim agreed to divest five types 
		of animal health products to settle charges that a proposed asset swap 
		with Sanofi would harm competition, the U.S. Federal Trade Commission 
		said on Wednesday. | 
        
            | 
			
			 The proposed asset swap involved Boehringer Ingelheim's acquisition 
			of Sanofi's $13.5 billion animal care subsidiary and Sanofi's 
			obtaining the Germany company's consumer health care business unit, 
			valued at nearly $8 billion, plus $5.5 billion in cash, the FTC said 
			in a statement. 
 Without the divestitures, the proposed swap "would harm competition 
			in the U.S. markets for various vaccines for companion animals 
			(pets) and certain parasite control products for cattle and sheep," 
			the commission said.
 
 The sale of the U.S. pet vaccine assets will occur shortly after the 
			closing of the BI-Sanofi swap transaction, which the company 
			anticipates to close by early 2017, Boehringer spokeswoman told 
			Reuters in an email.
 
			
			 
			Sanofi was not immediately available for comments.
 The FTC said that without the divestitures the proposed transaction 
			would reduce the number of suppliers of canine and feline vaccines 
			from four to three. It would combine the two top rabies vaccine 
			suppliers.
 
 It would also reduce competition among suppliers of products to 
			prevent parasites in cattle and sheep, the FTC said.
 
 In November the companies agreed to divestitures to allay European 
			Commission concerns that the deal would harm competition and 
			possibly result in price hikes.
 
			
            [to top of second column] | 
 
			"The two companies offered to divest a number of Merial's marketed 
			and pipeline products, including its existing vaccines Circovac, 
			Progressis, Parvovax, Parvovurax and Mucossifa and pharmaceuticals 
			Ketofen, Wellicox, Allevinix, Genixine, Equioxx Injectable and 
			Equioxx Paste," the EU said at the time.
 (Reporting by Doina Chiacu in Washington and Julie Steenhuysen in 
			Chicago; additional reporting by Gaurika Juneja in Bengaluru; 
			Editing by Marguerita Choy and David Gregorio)
 
			[© 2016 Thomson Reuters. All rights 
				reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed. 
			
			
			 |